Dutch antibody technology company BiosanaPharma is offering to make monoclonal antibodies at between 5% and 10% the usual cost of manufacture. Dr. Nettie Buitelaar, the company’s chief business officer, told Scrip’s Mike Ward that the company will license the technology to others making innovative molecules, helping them complete development of monoclonals, while retaining exclusive use for biosimilar production.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?